[Chinse expert consensus on issues related to the protection, treatment and management of patients with solid tumors during COVID-19 (2022 edition)].
Zhonghua Zhong Liu Za Zhi
; 44(10): 1083-1090, 2022 Oct 23.
Article
in Chinese
| MEDLINE | ID: covidwho-2099944
ABSTRACT
The new coronavirus is still in the global pandemic stage. At present, the Delta strain and the Omicron strain are the main circulating strains. The mutant strain has stronger infectivity than the original virus. In the content of COVID-19 pandemic, social public resources and medical resources may be affected, which lead to the medical treatment being delayed or interrupted in some patients with malignant tumors. Based on relevant research and clinical practice at home and abroad, the Cancer Support Therapy Committee of China Anti-Cancer Association and the Cancer Clinical Chemotherapy Committee of China Anti-Cancer Association, in the light of China's national conditions and the availability of resources such as vaccines and antiviral drug, to formulate a consensus of Chinese experts on issues related to the prevention, treatment and management of patients with solid tumors. The main contents include the vaccination of cancer patients with COVID-19, the optimization of medical resources, and the timing of restarting anti-tumor therapy after COVID-19 infection. This article is aimed at providing reference for clinical practice.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Neoplasms
Type of study:
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Country/Region as subject:
Asia
Language:
Chinese
Journal:
Zhonghua Zhong Liu Za Zhi
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS